A Double-Blind, Placebo-Controlled Study to Assess Pharmacodynamic and Clinical Efficacy of CYT003-QbG10 in Patients With Persistent Allergic Asthma Bronchial.

Trial Profile

A Double-Blind, Placebo-Controlled Study to Assess Pharmacodynamic and Clinical Efficacy of CYT003-QbG10 in Patients With Persistent Allergic Asthma Bronchial.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 May 2014

At a glance

  • Drugs CMP 001 (Primary)
  • Indications Allergic asthma; Hypersensitivity
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Sep 2013 Results from a post-hoc analysis of data published have been presented at the European Respiratory Society Annual Congress (ERS-2013) according to a Cytos Biotechnology media release. Results were also summarised in the media release.
    • 12 Nov 2010 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
    • 22 Sep 2010 Results were presented at the 20th Annual Congress of the European Respiratory Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top